Geode Capital Management LLC Buys 42,376 Shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)

Geode Capital Management LLC raised its stake in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 17.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 278,496 shares of the company’s stock after purchasing an additional 42,376 shares during the period. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent SEC filing.

Reviva Pharmaceuticals Price Performance

Shares of Reviva Pharmaceuticals stock opened at $1.88 on Monday. The firm has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $1.29. Reviva Pharmaceuticals Holdings, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $4.83. The company has a market cap of $62.87 million, a PE ratio of -1.69 and a beta of -0.12.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RVPH. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Friday. Roth Capital raised Reviva Pharmaceuticals to a “strong-buy” rating in a research report on Friday. Roth Mkm started coverage on Reviva Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $7.00 price objective for the company. Finally, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd. Four investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $11.25.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.